Growth Hormone
CJC-1295 (with DAC)
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Also known as: DAC-GRF, CJC-1295 DAC
Quick facts
Molecular weight
3,650 Da
Half-life
192 h
Frequency
weekly
Admins / wk
1
Routes
SubQ
Typical dose
1.00 mg–2.00 mg
Mechanism & positioning
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Researched for: sustained GHRH receptor agonism, elevated IGF-1 baseline.
Reconstitution defaults
Default vial
2 mg
BAC water
2 mL
Concentration
1000 mcg/mL
Doses per vial
~2
Other stocked vial sizes: 5 mg.
Calculate with this peptide
Documented pairwise interactions
- warning
CJC-1295 (with DAC) + CJC-1295 (no-DAC)
Short-acting and long-acting forms of the same GHRH analog; combining the two stacks receptor stimulation without literature support.
- caution
CJC-1295 (with DAC) + Ipamorelin
Long-acting GHRH paired with a short-acting GHRP — frequently co-investigated; ensure GHRP dosing remains conservative.
- warning
CJC-1295 (with DAC) + Tesamorelin
Both are GHRH analogs at the same receptor; the DAC long-acting form already maintains baseline stimulation.
References
- Ionescu M et al., J Clin Endocrinol Metab, 2006.
- Teichman SL et al., J Clin Endocrinol Metab, 2006.
Related peptides in the Growth Hormone class
CJC-1295 (no-DAC)
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
Ipamorelin
A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.
Tesamorelin
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Sermorelin
The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.
Hexarelin
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.
IGF1-LR3
A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.